Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims
March 21, 2017 at 12:33 PM EDT
BOSTON, March 21 (Reuters) - Sanofi SA and Regeneron Pharmaceuticals Inc filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.
